156 related articles for article (PubMed ID: 35480981)
1. Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy.
Bonifacius A; Tischer-Zimmermann S; Santamorena MM; Mausberg P; Schenk J; Koch S; Barnstorf-Brandes J; Gödecke N; Martens J; Goudeva L; Verboom M; Wittig J; Maecker-Kolhoff B; Baurmann H; Clark C; Brauns O; Simon M; Lang P; Cornely OA; Hallek M; Blasczyk R; Seiferling D; Köhler P; Eiz-Vesper B
Front Bioeng Biotechnol; 2022; 10():867042. PubMed ID: 35480981
[No Abstract] [Full Text] [Related]
2. Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes.
Chu Y; Milner J; Lamb M; Maryamchik E; Rigot O; Ayello J; Harrison L; Shaw R; Behbehani GK; Mardis ER; Miller K; Prakruthi Rao Venkata L; Chang H; Lee D; Rosenthal E; Kadauke S; Bunin N; Talano JA; Johnson B; Wang Y; Cairo MS
J Infect Dis; 2023 Mar; 227(6):788-799. PubMed ID: 36583990
[TBL] [Abstract][Full Text] [Related]
3. Comparative Analysis of Clinical-Scale IFN-γ-Positive T-Cell Enrichment Using Partially and Fully Integrated Platforms.
Priesner C; Esser R; Tischer S; Marburger M; Aleksandrova K; Maecker-Kolhoff B; Heuft HG; Goudeva L; Blasczyk R; Arseniev L; Köhl U; Eiz-Vesper B; Klöß S
Front Immunol; 2016; 7():393. PubMed ID: 27746781
[TBL] [Abstract][Full Text] [Related]
4. Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19.
García-Ríos E; Leivas A; Mancebo FJ; Sánchez-Vega L; Lanzarot D; Aguado JM; Martínez-López J; Paciello ML; Pérez-Romero P
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327433
[TBL] [Abstract][Full Text] [Related]
5. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.
Tischer S; Priesner C; Heuft HG; Goudeva L; Mende W; Barthold M; Kloeß S; Arseniev L; Aleksandrova K; Maecker-Kolhoff B; Blasczyk R; Koehl U; Eiz-Vesper B
J Transl Med; 2014 Dec; 12():336. PubMed ID: 25510656
[TBL] [Abstract][Full Text] [Related]
6. Vaccinated and Convalescent Donor-Derived Severe Acute Respiratory Syndrome Coronavirus 2-Specific T Cells as Adoptive Immunotherapy for High-Risk Coronavirus Disease 2019 Patients.
Papayanni PG; Chasiotis D; Koukoulias K; Georgakopoulou A; Iatrou A; Gavriilaki E; Giannaki C; Bitzani M; Geka E; Tasioudis P; Chloros D; Fylaktou A; Kioumis I; Triantafyllidou M; Dimou-Besikli S; Karavalakis G; Boutou AK; Siotou E; Anagnostopoulos A; Papadopoulou A; Yannaki E
Clin Infect Dis; 2021 Dec; 73(11):2073-2082. PubMed ID: 33905481
[TBL] [Abstract][Full Text] [Related]
7. Rapid production of clinical-grade SARS-CoV-2 specific T cells.
Leung W; Soh TG; Linn YC; Low JG; Loh J; Chan M; Chng WJ; Koh LP; Poon ML; Ng KP; Kuick CH; Tan TT; Tan LK; Seng MS
Adv Cell Gene Ther; 2020 Oct; 3(4):e101. PubMed ID: 32838213
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
9. Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19.
Cooper RS; Fraser AR; Smith L; Burgoyne P; Imlach SN; Jarvis LM; Turner DM; Zahra S; Turner ML; Campbell JDM
Front Immunol; 2020; 11():598402. PubMed ID: 33488592
[TBL] [Abstract][Full Text] [Related]
10. Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients?
Guerreiro M; Aguilar-Gallardo C; Montoro J; Francés-Gómez C; Latorre V; Luna I; Planelles D; Carrasco MP; Gómez MD; González-Barberá EM; Aguado C; Sempere A; Solves P; Gómez-Seguí I; Balaguer-Rosello A; Louro A; Perla A; Larrea L; Sanz J; Arbona C; de la Rubia J; Geller R; Sanz MÁ; Sanz G; Luis Piñana J
Transpl Infect Dis; 2021 Aug; 23(4):e13602. PubMed ID: 33728702
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants.
Panikkar A; Lineburg KE; Raju J; Chew KY; Ambalathingal GR; Rehan S; Swaminathan S; Crooks P; Le Texier L; Beagley L; Best S; Solomon M; Matthews KK; Srihari S; Neller MA; Short KR; Khanna R; Smith C
PLoS Pathog; 2022 Feb; 18(2):e1010339. PubMed ID: 35157735
[TBL] [Abstract][Full Text] [Related]
12. Robust Production of Cytomegalovirus pp65-Specific T Cells Using a Fully Automated IFN-γ Cytokine Capture System.
Kim N; Nam YS; Im KI; Lim JY; Jeon YW; Song Y; Lee JW; Cho SG
Transfus Med Hemother; 2018 Jan; 45(1):13-22. PubMed ID: 29593456
[TBL] [Abstract][Full Text] [Related]
13. Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment.
Kim N; Lee JM; Oh EJ; Jekarl DW; Lee DG; Im KI; Cho SG
Front Immunol; 2021; 12():751869. PubMed ID: 35003063
[TBL] [Abstract][Full Text] [Related]
14. Comparison between enzyme-linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS-CoV-2 after symptomatic COVID-19.
Villemonteix J; Cohen L; Guihot A; Guérin V; Moulin C; Caseris M; Carol A; Bonacorsi S; Carcelain G
Immun Inflamm Dis; 2022 Oct; 10(10):e617. PubMed ID: 36169252
[TBL] [Abstract][Full Text] [Related]
15. Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy.
Feuchtinger T; Lang P; Hamprecht K; Schumm M; Greil J; Jahn G; Niethammer D; Einsele H
Exp Hematol; 2004 Mar; 32(3):282-9. PubMed ID: 15003314
[TBL] [Abstract][Full Text] [Related]
16. Rapid and sustained T cell-based immunotherapy against invasive fungal disease via a combined two step procedure.
Tischer-Zimmermann S; Salzer E; Bitencourt T; Frank N; Hoffmann-Freimüller C; Stemberger J; Maecker-Kolhoff B; Blasczyk R; Witt V; Fritsch G; Paster W; Lion T; Eiz-Vesper B; Geyeregger R
Front Immunol; 2023; 14():988947. PubMed ID: 37090716
[TBL] [Abstract][Full Text] [Related]
17. Effective virus-specific T-cell therapy for high-risk SARS-CoV-2 infections in hematopoietic stem cell transplant recipients: initial case studies and literature review.
Gopcsa L; Réti M; Andrikovics H; Bobek I; Bekő G; Bogyó J; Ceglédi A; Dobos K; Giba-Kiss L; Jankovics I; Kis O; Lakatos B; Mathiász D; Meggyesi N; Miskolczi G; Németh N; Paksi M; Riczu A; Sinkó J; Szabó B; Szilvási A; Szlávik J; Tasnády S; Reményi P; Vályi-Nagy I
Geroscience; 2024 Feb; 46(1):1083-1106. PubMed ID: 37414968
[TBL] [Abstract][Full Text] [Related]
18. GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy.
Fernández L; Fernández A; Mirones I; Escudero A; Cardoso L; Vela M; Lanzarot D; de Paz R; Leivas A; Gallardo M; Marcos A; Romero AB; Martínez-López J; Pérez-Martínez A
Front Immunol; 2019; 10():2361. PubMed ID: 31649672
[TBL] [Abstract][Full Text] [Related]
19. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
20. Detection of IFNγ-Secreting CD4
Matyushenko V; Isakova-Sivak I; Kudryavtsev I; Goshina A; Chistyakova A; Stepanova E; Prokopenko P; Sychev I; Rudenko L
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
